Hikma Pharmaceuticals (HKMPF)
(Delayed Data from OTC)
$25.16 USD
0.00 (0.00%)
Updated Oct 3, 2024 02:53 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HKMPF 25.16 0.00(0.00%)
Will HKMPF be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HKMPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HKMPF
Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know
HKMPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HKMPF
Hikma Pharmaceuticals just upgraded at Berenberg, here's why
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Hikma price target raised to 2,100 GBp from 2,000 GBp at Berenberg
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Pre-Recorded Presentation Transcript